Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
- Conditions
- Fabry Disease
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 78
- Registration Number
- NCT06052800
- Locations
- 🇨🇳
Investigational Site Number : 1580004, Taichung, Taiwan
🇨🇳Investigational Site Number : 1580005, Tainan City, Taiwan
🇨🇳Investigational Site Number : 1580001, Taipei City, Taiwan
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 900
- Registration Number
- NCT06039241
- Locations
- 🇩🇪
Investigational Site Number: 186, Karlsruhe, Germany
🇩🇪Investigational Site Number: 069, Köln, Germany
🇩🇪Investigational Site Number: 004, Berlin, Germany
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 335
- Registration Number
- NCT06033833
- Locations
- 🇵🇱
Investigational Site Number : 6160003, Elblag, Poland
🇵🇱Investigational Site Number : 6160002, Gdansk, Poland
🇺🇸Bensch Research Associates- Site Number : 8400004, Stockton, California, United States
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Drug: SAR444656 (KT-474)Drug: Placebo
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 156
- Registration Number
- NCT06028230
- Locations
- 🇺🇸
Dawes Fretzin Clinical Research Group LLC Site Number : 8400011, Indianapolis, Indiana, United States
🇺🇸Clear Dermatology & Aesthetics Center Scottsdale Site Number : 8400006, Scottsdale, Arizona, United States
🇺🇸First OC Dermatology Site Number: 8400007, Fountain Valley, California, United States
A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme
- Conditions
- Fabry's Disease
- Interventions
- Drug: AGALSIDASE BETA (GZ419828)
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8
- Registration Number
- NCT06019728
- Locations
- 🇺🇸
UCLA Medical Center Site Number : 1003, Santa Monica, California, United States
🇺🇸Emory University School of Medicine Site Number : 1005, Atlanta, Georgia, United States
🇺🇸Infusion Associates Site Number : 1001, Grand Rapids, Michigan, United States
A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting
- Conditions
- Asthma
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 112
- Registration Number
- NCT06018441
- Locations
- 🇫🇷
Investigational Site, France, France
A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo
- Conditions
- Dermatitis Atopic
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 215
- Registration Number
- NCT06015308
- Locations
- 🇺🇸
Clinical Research Center of Alabama - Homewood- Site Number : 8401101, Birmingham, Alabama, United States
🇺🇸Center for Dermatology and Plastic Surgery- Site Number : 8401119, Scottsdale, Arizona, United States
🇺🇸Orange County Clinical Trials- Site Number : 8401271, Anaheim, California, United States
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 300
- Registration Number
- NCT05991323
- Locations
- 🇫🇷
Investigational Site Number : 2500005, Brest, Finistère, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
🇯🇵Investigational Site Number : 3920001, Obihiro, Hokkaido, Japan
A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT05983068
- Locations
- 🇺🇸
National Jewish Health Medical Center- Site Number : 8400001, Denver, Colorado, United States
🇺🇸SSM Health Saint Louis University Hospital- Site Number : 8400006, Saint Louis, Missouri, United States
🇺🇸NYU Langone Medical Center- Site Number : 8400004, New York, New York, United States
A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 38
- Registration Number
- NCT05976373
- Locations
- 🇺🇸
Prism Research-Site Number:840001, Saint Paul, Minnesota, United States